|
Growing Pains at Camelot Biopharmaceuticals
Lynn Johnson Langer Johns Hopkins University Summary of key issue: This case study for Camelot Biopharmaceuticals (name disguised), a development stage biotechnology company, focuses on the board of directors’ assessment of the CEO. Using management team interviews from a 360 degree performance assessment, the Board must assess the CEO’s performance and potential for future growth. Although Camelot had advanced products into early stage clinical trials, the organization as a whole still maintained a highly scientific and research focus as the company was evolving towards a focus on product development and strategic alliances. Key words: leadership, decision making, management, scientist founders, leadership style |
Building the Case for Biotechnology is published by Logos Press